Showing 1611-1620 of 2314 results for "".
- US to Buy 500 Million Doses of Pfizer, BioNTech COVID-19 Vaccine for Donation to Poorest Nationshttps://modernod.com/news/us-to-buy-500-million-doses-of-pfizer-biontech-covid-19-vaccine-for-donation-to-poorest-nations/2479284/Pfizer and BioNTech said Thursday that they will provide 500 million doses of the COVID-19 vaccine BNT162b2 to the US government at a not-for-profit price to support immunization programs in low- and lower-middle-income countries, according to FirstWord. The companies noted that 200 million doses
- Lighthouse Guild Announces the Naming of The Dorothy Strelsin Behavioral Health Clinichttps://modernod.com/news/lighthouse-guild-announces-the-naming-of-the-dorothy-strelsin-behavioral-health-clinic/2479278/In recognition of a long-time supporter of Lighthouse Guild, the organization has announced the naming of The Dorothy Strelsin Behavioral Health Clinic. Lighthouse Guild is very grateful for the steadfast support of Dorothy Strelsin, who in her lifetime made numerous initiatives possible, includi
- Outlook Therapeutics Completes Patient Dosing in Phase 3 NORSE TWO Trial for Wet AMDhttps://modernod.com/news/outlook-therapeutics-completes-patient-dosing-in-phase-3-norse-two-trial-for-wet-amd/2479279/Outlook Therapeutics reported that it has administered the final dose to the last patient enrolled in its pivotal NORSE TWO safety and efficacy study evaluating ONS-5010 (bevacizumab-vikg) for treatment of wet age-related macular degeneration (AMD). Topline data are expected to be reported for NO
- EU Signs Deal With BioNTech, Pfizer for Further 1.8 Billion COVID-19 Vaccine Doseshttps://modernod.com/news/eu-signs-deal-with-biontech-pfizer-for-further-1-8-billion-covid-19-vaccine-doses/2479234/The European Commission announced the signing of a third contract with BioNTech and Pfizer for the supply of up to 1.8 billion COVID-19 vaccine doses between the end of this year and 2023, according to a FirstWord report. The deal, which had been agreed earlier this month, allows for the purchase
- Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302 Anti-VEGF for Wet AMDhttps://modernod.com/news/innovent-announces-first-patient-dosed-in-the-phase-2-clinical-trial-of-ibi302-anti-vegf-for-wet-amd/2479137/Innovent Biologics announces that the first patient has been successfully dosed in a phase 2 clinical trial for IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein. This study is a randomized, double-blind, multicenter, active-cont
- Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.https://modernod.com/news/alcon-launches-systane-hydration-multi-dose-preservative-free-lubricant-eye-drops-in-the-u-s/2479131/Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of the newest addition to its innovative portfolio of dry eye products – Systane® Hydration Multi-Dose Preservative-Free (MDPF) Lubricant Eye Dro
- DORC Launches EVA Aveta Trocar Cannula Systemhttps://modernod.com/news/dorc-launches-eva-aveta-trocar-cannula-system/2479129/DORC is launching the new EVA Aveta trocar cannula system, the first system to feature the patent-pending Push-Fit infusion connection, plus a laser-etched retention feature, according to a company news release. Benef
- David R. Guyer, MD, to Step Down from Iveric Bio Board to Rejoin Venture Fundhttps://modernod.com/news/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund/2479050/Iveric bio announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio’s 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021. Dr. Guyer has served as the Chairman of Iveric’
- UMass Medical School and AEYE Health Leverage AI to Help Family Doctors Screen and Refer Patients With Eye Conditions to Specialistshttps://modernod.com/news/umass-medical-school-and-aeye-health-leverage-ai-to-help-family-doctors-screen-and-refer-patients-with-eye-conditions-to-specialists/2479031/AEYE Health and UMass Medical School, in collaboration with UMass Memorial Health Care, are developing a system which enables family doctors to screen patients for various retinal conditions and enable timely referrals to specialists. As part of this effort, AEY
- Clearside Biomedical Completes Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-patient-dosing-in-first-cohort-of-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478927/Clearside Biomedical announced completion of dosing in the first cohort of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicenter,